Welcome to our dedicated page for Inovio Pharmaceu news (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceu stock.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is a biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The INO news feed on Stock Titan aggregates company-issued press releases, regulatory updates, and other market-moving disclosures so readers can follow how INOVIO’s DNA medicine programs progress over time.
A major focus of recent INOVIO news is INO-3107, an investigational DNA medicine for adults with recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract. Updates include completion of a rolling Biologics License Application (BLA), FDA acceptance of the BLA for review under a Standard classification, and discussion of the accelerated approval pathway. News items also highlight clinical data showing reductions in the number of surgeries required by trial participants and long-term durability results from retrospective analyses.
Investors can also find announcements on capital-raising transactions, such as underwritten public offerings of common stock and warrants disclosed in Form 8-K filings and related press releases. INOVIO frequently reports on financial results, including quarterly earnings releases, as well as corporate governance and compensation matters like inducement stock option grants under its Inducement Plan.
Additional coverage includes scientific and clinical milestones, such as publication of Phase 1 proof-of-concept data for DNA-Encoded Monoclonal Antibody (DMAb) technology in Nature Medicine and preclinical progress in DNA-encoded protein (DPROT) programs. Conference participation and investor events are also regular topics. For followers of INO stock, this news page offers a centralized view of the company’s clinical, regulatory, financial, and strategic communications.
INOVIO has received authorization from Mexico's COFEPRIS to conduct Phase 3 clinical trials for its COVID-19 DNA vaccine candidate, INO-4800, as part of the global INNOVATE trial. This development, alongside previous authorizations in Brazil and the Philippines, positions INOVIO to assess the vaccine's efficacy in adults. The Phase 3 trial aims to evaluate a two-dose regimen with a primary endpoint of confirmed COVID-19 cases. INO-4800 is notable for its safety profile and thermostability, potentially contributing to the global pandemic response.
INOVIO (NASDAQ:INO) has announced that Dr. Joseph Kim, President and CEO, will present at three upcoming investor conferences in September 2021. The conferences include:
- H.C. Wainwright 23rd Annual Global Investment Conference - Sept 13-15, recorded presentation available on-demand.
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit - Sept 21, at 9:55 AM ET, fireside chat format.
- Cantor Fitzgerald Healthcare Conference - Sept 27, at 10:00 AM ET, fireside chat format.
Details on accessing these presentations can be found on INOVIO's Investor Relations page.
INOVIO (NASDAQ: INO) announced regulatory approval from Brazil's ANVISA to proceed with the global Phase 3 segment of the INNOVATE trial for its DNA vaccine candidate INO-4800 against COVID-19. This trial will assess the efficacy of a two-dose regimen in several countries, targeting adults aged 18 and older. The trial aims to confirm the vaccine's safety and immunogenicity, building on positive Phase 2 results. INO-4800 is characterized as stable at room temperature, well-tolerated, and scalable for mass distribution, offering potential advantages in combating COVID-19.
INOVIO (NASDAQ: INO) reported a net loss of $82.1 million, or $0.39 per share, for Q2 2021, compared to a loss of $128.7 million, or $0.83 per share, in Q2 2020. Total revenue slightly increased to $273,000 from $267,000. Operating expenses rose to $83.5 million from $33.4 million, driven primarily by R&D costs associated with manufacturing scale-up for COVID-19 vaccine INO-4800. INOVIO continues advancing its COVID-19 vaccine initiatives, including the INNOVATE Phase 3 trial and the new pan-COVID-19 vaccine INO-4802.
INOVIO (NASDAQ:INO) announced regulatory approval to initiate two clinical trials in China for its COVID-19 DNA vaccine candidate, INO-4800. The trials, sponsored by Advaccine Biopharmaceuticals and Sinovac, will investigate the safety and immunogenicity of a heterologous prime-boost regimen with INO-4800 and Sinovac's CoronaVac. Following successful preclinical results demonstrating strong immune responses, the trials aim to enhance vaccination strategies against emerging COVID-19 variants. If successful, INO-4800 could serve as both a primary and booster vaccine.
INOVIO (NASDAQ: INO) has commenced Phase 2 trials for INO-4700, a DNA vaccine aimed at combating the Middle East Respiratory Syndrome (MERS). This multi-center study, involving around 500 healthy volunteers in Jordan and Lebanon, seeks to assess the safety and immunogenicity of the vaccine. The trial builds on promising results from a previous Phase 1 trial, where 98% of participants developed an immune response. Funded by a $56 million CEPI grant, INOVIO aims to provide a preventive vaccine against MERS, a deadly disease with a high fatality rate.
INOVIO (NASDAQ: INO) will release its second quarter 2021 financial results on August 9, 2021, after market close. A conference call will follow at 4:30 p.m. ET, providing insights into its DNA Medicines Platform and ongoing COVID-19 vaccine developments. The company aims to address financial results and business updates.
Notably, INOVIO's lead candidate VGX-3100 has shown promising results in clearing high-grade cervical lesions in clinical trials, while INO-4800 is currently in Phase 2 trials for COVID-19.
INOVIO (NASDAQ: INO) announced an expansion of its partnership with Advaccine Biopharmaceuticals to conduct a global Phase 3 trial for INO-4800, a DNA vaccine targeting COVID-19. The trial will evaluate the safety and efficacy of a two-dose regimen in adults across Latin America and Asia, with an emphasis on underserved regions. The Phase 3 trial follows promising Phase 2 results showing INO-4800's good tolerance and immunogenicity. The estimated cost of the trial is about $100 million, which will be shared equally with Advaccine.
Geneos Therapeutics announced positive preliminary results from its GT-30 trial, a phase I/II study of personalized vaccine GNOS-PV02 combined with pIL-12 and pembrolizumab for patients with advanced hepatocellular carcinoma (HCC). Out of 10 evaluable patients, the overall response rate was 30%, with 3 achieving partial response and 7 exhibiting disease control. The treatment was generally safe, with no serious adverse events reported. Additionally, interim results from a compassionate use case showed a patient with anaplastic astrocytoma remained recurrence-free for 36 months after treatment.
INOVIO (NASDAQ:INO) announced participation in the Jefferies 2021 Virtual Healthcare Conference on June 1, 2021. Dr. Joseph Kim, President and CEO, will engage in a fireside chat and 1x1 investor meetings at 2:00 PM EDT. INOVIO focuses on developing DNA medicines for infectious diseases, cancer, and HPV-associated conditions, with 15 clinical programs underway. Their proprietary delivery device, CELLECTRA®, allows plasmids to enter cells, generating immune responses without altering individual DNA. INOVIO has conducted over 7,000 applications in clinical trials, showcasing robust efficacy in various programs.